Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Enhancing vaccine safety capacity globally: A lifecycle perspective.

Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M.

Vaccine. 2015 Nov 27;33 Suppl 4:D46-54. doi: 10.1016/j.vaccine.2015.06.073. Epub 2015 Oct 1. Review.

2.

Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century.

Poland GA, Kennedy RB, McKinney BA, Ovsyannikova IG, Lambert ND, Jacobson RM, Oberg AL.

Semin Immunol. 2013 Apr;25(2):89-103. doi: 10.1016/j.smim.2013.04.007. Epub 2013 Jun 5. Review.

3.

Vaccination against Lyme disease: past, present, and future.

Embers ME, Narasimhan S.

Front Cell Infect Microbiol. 2013 Feb 12;3:6. doi: 10.3389/fcimb.2013.00006. eCollection 2013. Review.

4.

Induction of Experimental Arthritis by Borrelial Lipoprotein and CpG Motifs: Are Toll-Like Receptors 2, 4, 9 or CD-14 Involved?

Batsford S, Dunn J, Mihatsch M.

Open Rheumatol J. 2011;5:18-23. doi: 10.2174/1874312901105010018. Epub 2011 Jul 19.

5.

Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease.

Pozsgay V, Kubler-Kielb J, Coxon B, Marques A, Robbins JB, Schneerson R.

Carbohydr Res. 2011 Sep 6;346(12):1551-63. doi: 10.1016/j.carres.2011.04.045. Epub 2011 May 3.

6.

Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis.

Steere AC, Drouin EE, Glickstein LJ.

Clin Infect Dis. 2011 Feb;52 Suppl 3:s259-65. doi: 10.1093/cid/ciq117. Review.

Supplemental Content

Support Center